Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
| Index | NYSE Arca Biotechnology |
| Investment focus | Equity, United States, Health Care |
| Fund size | EUR 12 m |
| Total expense ratio | 0.60% p.a. |
| Replication | Physical (Full replication) |
| Legal structure | ETF |
| Strategy risk | Long-only |
| Sustainability | No |
| Fund currency | USD |
| Currency risk | Currency unhedged |
| Volatility 1 year (in EUR) | 23.76% |
| Inception/ Listing Date | 27 May 2020 |
| Distribution policy | Accumulating |
| Distribution frequency | - |
| Fund domicile | Ireland |
| Fund Provider | First Trust |
| Fund Structure | Open-ended Investment Company (OEIC) |
| UCITS compliance | Yes |
| Administrator | BNY Mellon Fund Services (Ireland) Designated Activity Company |
| Investment Advisor | First Trust Advisors L.P. |
| Custodian Bank | The Bank of New York Mellon SA/NV, Dublin Branch |
| Revision Company | PwC |
| Fiscal Year End | 31 December |
| Swiss representative | Oligo Swiss Fund Services SA |
| Swiss paying agent | Banque Cantonale de Genève |
| Germany | 30% tax rebate |
| Switzerland | ESTV Reporting |
| Austria | Tax Reporting Fund |
| UK | UK Reporting |
| Indextype | Total return index |
| Swap counterparty | - |
| Collateral manager | |
| Securities lending | No |
| Securities lending counterparty |
| Illumina, Inc. | 4.15% |
| Natera | 3.71% |
| Regeneron Pharmaceuticals, Inc. | 3.64% |
| ACADIA Pharmaceuticals | 3.57% |
| Incyte Corp. | 3.52% |
| Mettler-Toledo Intl | 3.51% |
| EXACT Sciences Corp. | 3.50% |
| Bruker | 3.48% |
| Krystal Biotech | 3.43% |
| Sarepta Therapeutics | 3.43% |
| United States | 84.46% |
| Germany | 3.21% |
| Ireland | 3.10% |
| Other | 9.23% |
| Health Care | 90.77% |
| Other | 9.23% |
| YTD | +14.04% |
| 1 month | +10.21% |
| 3 months | +21.35% |
| 6 months | +26.86% |
| 1 year | +9.83% |
| 3 years | +21.28% |
| 5 years | +34.90% |
| Since inception (MAX) | +22.95% |
| 2024 | +12.26% |
| 2023 | -1.30% |
| 2022 | +1.20% |
| 2021 | +4.30% |
| Volatility 1 year | 23.76% |
| Volatility 3 years | 20.31% |
| Volatility 5 years | 22.18% |
| Return per risk 1 year | 0.41 |
| Return per risk 3 years | 0.33 |
| Return per risk 5 years | 0.28 |
| Maximum drawdown 1 year | -24.57% |
| Maximum drawdown 3 years | -24.57% |
| Maximum drawdown 5 years | -24.57% |
| Maximum drawdown since inception | -25.05% |
| Listing | Trade Currency | Ticker | Bloomberg / iNAV Bloomberg Code | Reuters RIC / iNAV Reuters | Market Maker |
|---|---|---|---|---|---|
| Borsa Italiana | EUR | FBT | FBT IM FBTINAV | FBT.MI | |
| London Stock Exchange | GBX | FBT | FBT LN FBTINAV | ||
| London Stock Exchange | GBP | - | FBT LN | ||
| London Stock Exchange | USD | FBTU | FBTU LN FBTINAV |
| Fund name | Fund Size in m € (AuM) | TER p.a. | Distribution | Replication |
|---|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 44 | 0.35% p.a. | Distributing | Sampling |